Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer

References

• Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9:139–50
   PubMed Web of Science ®Google Scholar
• Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med 2003;228:995–1003
   PubMed Web of Science ®Google Scholar
• Gómez-Muñoz A. Ceramide 1-phosphate/ceramide, a switch between life and death. Biochim Biophys Acta 2006;1758:2049–56
   PubMed Web of Science ®Google Scholar
• Struckhoff AP, Bittman R, Burow ME, et al Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 2004;309:523–32
   PubMed Web of Science ®Google Scholar
• Dahm F, Bielawska A, Nocito A, et al Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice. Br J Cancer 2008;98: 98–105
   PubMed Web of Science ®Google Scholar
• Mehta S, Blackinton D, Omar I, et al Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line. Cancer Chemother Pharmacol 2000;46:85–92
   PubMed Web of Science ®Google Scholar
• Ogretmen B. Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS Lett 2006. 580:5467–76
   Google Scholar
• Smith ER, Merrill, AH, Obeid LM, Hannun YA. Effects of sphingosine and other sphingolipids on protein kinase C. Methods Enzymol 2000;312: 361–73
   PubMed Web of Science ®Google Scholar
• Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4:397–407
   PubMed Web of Science ®Google Scholar
• Ruckhaberle E, Rody A, Engels K, et al Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008;112:41–52
   PubMed Web of Science ®Google Scholar
• Rody A, Holtrich U, Gaetje R, et al Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res 2007;13:1115–22
   PubMed Web of Science ®Google Scholar
• Ahr A, Karn T, Solbach C, et al Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002;359:131–2
   PubMed Web of Science ®Google Scholar
• Miller LD, Smeds J, George J, et al An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005;102:13550–5
   PubMed Web of Science ®Google Scholar
• Pawitan Y, Bjohle J, Amler L, et al Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005;7:R953–64
   PubMed Web of Science ®Google Scholar
• Wang Y, Klijn JG, Zhang Y, et al Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671–9
   PubMed Web of Science ®Google Scholar
• Minn AJ, Gupta GP, Padua D, et al Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 2007;104:6740–5
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S, et al Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262–72
   PubMed Web of Science ®Google Scholar
• Loi S, Haibe-Kains B, Desmedt C, et al Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25: 1239–46
   PubMed Web of Science ®Google Scholar
• Minn AJ, Gupta GP, Siegel PM, et al Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518–24
   PubMed Web of Science ®Google Scholar
• Desmedt C, Piette F, Loi S, et al TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207–14
   PubMed Web of Science ®Google Scholar
• The International Genomics Consortium (IGC). The expo project (Expression Project For Oncology). http://www.intgen.org/
   Google Scholar
• Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001;98:31–6
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15
   PubMed Web of Science ®Google Scholar
• Foekens JA, Atkins D, Zhang Y, et al Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006;24: 1665–71
   PubMed Web of Science ®Google Scholar
• Gong Y, Yan K, Lin F, et al Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007;8:203–11
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Potti A, Delorenzi M, et al Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007;8:1071–8
   PubMed Web of Science ®Google Scholar
• Alexe G, Dalgin GS, Scanfeld D, et al High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007. 67:10669–76
   Google Scholar
• Rody A, Karn T, Ruckhäberle E, et al Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers. Results of a large scale microarray analysis. Eur J Cancer 2009. 45:405–13
   PubMed Web of Science ®Google Scholar
• Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006;1758;2016–26
   PubMed Web of Science ®Google Scholar
• Smith ER, Merrill AH, Obeid LM, Hannun YA. Effects of sphingosine and other sphingolipids on protein kinase C. Methods Enzymol 2000. 312:361–73
   PubMed Web of Science ®Google Scholar
• Ahn EH, Chang CC, Schroeder JJ. Evaluation of sphinganine and sphingosine as human breast cancer chemotherapeutic and chemopreventive agents. Exp Biol Med 2006;231:1664–72
   Web of Science ®Google Scholar
• Igarashi Y, Kitamura K, Toyokuni T, et al A specific enhancing effect of N,N-dimethylsphingosine on epidermal growth factor receptor autophosphorylation. Demonstration of its endogenous occurrence (and the virtual absence of unsubstituted sphingosine) in human epidermoid carcinoma A431 cells. J Biol Chem 1990;265: 5385–9
   PubMed Web of Science ®Google Scholar
• Goldkorn T, Dressler KA, Muindi J, et al Ceramide stimulates epidermal growth factor receptor phosphorylation in A431 human epidermoid carcinoma cells. Evidence that ceramide may mediate sphingosine action. J Biol Chem 1991;266:16092–7
   PubMed Web of Science ®Google Scholar
• Riboni L, Campanella R, Bassi R, et al Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 2002;39: 105–13
   PubMed Web of Science ®Google Scholar
• Rylova SN, Somova OG, Dyatlovitskaya EV. Comparative investigation of sphingoid bases and fatty acids in ceramides and sphingomyelins from human ovarian malignant tumors and normal ovary. Biochemistry (Moscow) 1998. 63:1057–60
   PubMed Web of Science ®Google Scholar
• Pewzner-Jung Y, Ben-Dor S, Futerman AH. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. J Biol Chem 2006;281:25001–5
   PubMed Web of Science ®Google Scholar
• Venkataraman K, Riebeling C, Bodennec J, et al Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro) ceramide) synthesis in a fumonisin B1-independent manner in mammalian cells. J Biol Chem 2002;277:35642–9
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Kihara A, Igarashi Y. Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J 2005;390:263–71
   PubMed Web of Science ®Google Scholar
• Lahiri S, Futerman AH. LASS5 is a bona fide dihydroceramide synthase that selectively utilizes palmitoyl-CoA as acyl donor. J Biol Chem 2005;280:33735–8
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Kihara A, Igarashi Y. LASS3 (longevity assurance homologue 3) is a mainly testis-specific (dihydro)ceramide synthase with relatively broad substrate specificity. Biochem J 2006;398:531–8
   PubMed Web of Science ®Google Scholar
• Riebeling C, Allegood JC, Wang E, Merrill AH Jr, Futerman AH. Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J Biol Chem 2003;278:43452–9
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhou J, McCoy DM, Mallampalli RK. LASS5 is the predominant ceramide synthase isoform involved in de novo sphingolipid synthesis in lung epithelial. J Lipid Res 2005;46: 1229–38
   PubMed Web of Science ®Google Scholar
• van Hall T, Wolpert EZ, van Veelen P, et al Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 2006;12:417–24
   PubMed Web of Science ®Google Scholar
• Koybasi S, Senkal CE, Sundararaj K, et al Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem 2004;279:44311–19
   PubMed Web of Science ®Google Scholar
• Senkal CE, Ponnusamy S, Rossi MJ, et al Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 2007;6:712–22
   PubMed Web of Science ®Google Scholar
• Karahatay S, Thomas K, Koybasi S, et al Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett 2007;256:101–11
   PubMed Web of Science ®Google Scholar
• Sylvester R, Collette L, Duchateau L. The role of meta-analyses in assessing cancer treatments. Eur J Cancer 2000;36:1351–8
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Cardoso F, de Castro G Jr, et al Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504–13
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, Caldas C. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res 2008;10:R73
   PubMedGoogle Scholar
• Györffy B, Schäfer R. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res Treat 2008 Dec 5. [Epub ahead of print].
   PubMedGoogle Scholar
• Wirapati P, Sotiriou C, Kunkel S, et al Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008;10:R65
   PubMed Web of Science ®Google Scholar
• Reyal F, van Vliet MH, Armstrong NJ, et al A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 2008;10:R93
   PubMedGoogle Scholar
• van Vliet MH, Reyal F, Horlings HM, van de Vijver MJ, Reinders MJ, Wessels LF. Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics 2008;9:375
   PubMed Web of Science ®Google Scholar